Logo

LEO Reports the US FDA's Acceptance of BLA for Tralokinumab to Treat Adults with Moderate to Severe Atopic Dermatitis

Share this

LEO Reports the US FDA's Acceptance of BLA for Tralokinumab to Treat Adults with Moderate to Severe Atopic Dermatitis

Shots:

  • The BLA submission is based on P-III ECZTRA 1 & 2 studies assessing tralokinumab (300mg- SC) as monothx. vs PBO in 804 & 794 adults with mod. to sev. AD who were candidates for systemic therapy for 52wks. respectively
  • The submission also follows the P-III ECZTRA 3 study assesses the safety and efficacy of tralokinumab (300mg- SC) + TCS in 380 adults with mod. to sev. AD who were candidates for systemic therapy
  • Tralokinumab is an IgG4 mAb act by neutralizing the IL-13 cytokine with its anticipated PDUFA date in Q2’21. The EMA has accepted MAA for tralokinumab and is under CHMP’s review for approval

Click here to read full press release/ article | Ref: PRNewswire | Image: GMP News


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions